MG-132

Catalog No.S2619

MG-132 is an inhibitor of proteasome with IC50 of 100 nM in a cell-free assay, and also inhibits calpain with IC50 of 1.2 μM.

Price Stock Quantity  
USD 100 In stock
USD 50 In stock
USD 170 In stock
USD 470 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

MG-132 Chemical Structure

MG-132 Chemical Structure
Molecular Weight: 475.62

Validation & Quality Control

Cited by 44 publications:

9 customer reviews :

Quality Control & MSDS

Related Compound Libraries

MG-132 is available in the following compound libraries:

Proteasome Inhibitors with Unique Features

Product Information

  • Compare Proteasome Inhibitors
    Compare Proteasome Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description MG-132 is an inhibitor of proteasome with IC50 of 100 nM in a cell-free assay, and also inhibits calpain with IC50 of 1.2 μM.
Targets Proteasome [1]
(Cell-free assay)
IC50 100 nM
In vitro MG-132 displays >1000 times more activity than ZLLal in inhibiting the ZLLL-MCA-degrading activity of 20S proteasome with IC50 of 100 nM versus 110 μM. MG-132 also inhibits calpain with IC50 of 1.2 μM. MG-132 induces neurite outgrowth in PC12 cells at an optimal concentration of 20 nM, displaying 500 times more potency than ZLLal. [1] MG-132 (10 μM) potently inhibits TNF-α-induced NF-κB activation, interleukin-8 (IL-8) gene transcription, and IL-8 protein release in A549 cells by inhibition of proteasome-mediated IκBα degradation. [2] MG-132 treatment potently induces p53-dependent apoptosis in KIM-2 cells by 26S proteasome inhibition. [3] Unlike BzLLLCOCHO or PS-341, MG-132 treatment results in weak inhibition of the chymotrypsinlike (CT-L) and peptidylglutamyl peptide hydrolysing (PGPH) activities of the 26S proteasome, whereas multiple myeloma cells (U266 and OPM-2) are more sensitive to induction of apoptosis by MG-132 than BzLLLCOCHO. [4] MG-132 (1 μM) sensitizes TRAIL-resistant prostate cancer cells by activating the AP-1 family members c-Fos and c-Jun, which, in turn, repress the antiapoptotic molecule c-FLIP(L). [5] MG-132 significantly enhances the ability of inositol hexakisphosphate (IP6) to reduce cellular metabolic activity in both PC3 and DU145 androgen-independent prostate cancer (AIPCa) cell lines. [6]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
LPS-stimulated RAW264.7 cellsNYfNTGJpTnWwY4Tpc44hSXO|YYm=MXSyOUDPxE1?NUDGWlhDTE2VTx?=MVrJcohq[mm2czDubZRzcWNib4jp[IUheHKxZIXjeIlwdiC5aYToJGlEPTBib3[gNE4yKM7:TR?=MkLCNlQ3QTd2OU[=
HL-60NEXDdIFEgXSxdH;4bYMhSXO|YYm=M33oNFQxKM7:TR?=MlG5OFghcA>?NWrpTJlMTE2VTx?=MVvJR|UxRDFyIN88US=>NH7GWXQzPDZ7N{S5Oi=>
SMMC-7721MmjmR5l1d3SxeHnjJGF{e2G7MVe0NEDPxE1?MXu0PEBpM322R2ROW09?NXzzfGJFUUN3ME23MlEh|ryPMlHXNlQ3QTd2OU[=
A-549NFO1SndEgXSxdH;4bYMhSXO|YYm=NHjkSY01OCEQvF2=NXnHU3V3PDhiaB?=M{Dle2ROW09?M3\GPGlEPTB:MUCg{txONYPPe4tiOjR4OUe0PVY>
MCF-7MmK3R5l1d3SxeHnjJGF{e2G7NEHrfFc1OCEQvF2=NVn3bWFMPDhiaB?=MkTtSG1UVw>?NFnrXGpKSzVyPUeuN{DPxE1?NGLwcJgzPDZ7N{S5Oi=>
SW-480M3rnV2N6fG:2b4jpZ{BCe3OjeR?=Mme1OFAh|ryPNHjhe4M1QCCqM4Dad2ROW09?NWSwTJdDUUN3ME20JO69VQ>?MkS4NlQ3QTd2OU[=
NCI-H929MnzRR5l1d3SxeHnjJGF{e2G7MVqxJO69VQ>?M1riTVczKGh?NWOy[ZE{TE2VTx?=NEntfHZKSzVyPUCuNVch|ryPNVP1dlJJOjR4MkWwPFg>
293TM{S4UmN6fG:2b4jpZ{BCe3OjeR?=NHWyOmUyOCEQvF2=Mn3IO|IhcA>?NFHPenZFVVORNYTpdZpCUUN3MEyyJO69VQ>?NUDNVnpsOjR4MkWwPFg>
293TNYfVVGlJTnWwY4Tpc44hSXO|YYm=MX[xNEDPxE1?NGq3eXEzPCCqMo[4SG1UVw>?NHXlWZpOd2SncnH0[Yx6KGmwZIXj[ZMhcGWjdD3zbI9kcyBiNE[5ZoUzPDZ{NUC4PC=>
HeLaMlPTT4lv[XOnIFHzd4F6MkC3NVAh|ryPMUKxJIg>NFLPVmNFVVORNYm0NnF3UW6mdXPld{BRSVKSIHPs[YF3[WenIHL5JIlvcGmkaYTpcocheHKxc3Xhd49u\SCjY4Tpeol1gQ>?NWrUdm1COjR|MkG4N|M>
MDA-MB-231NELuN2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUOxJO69VQ>?MYC3NkBpNX7QfWI5TE2VTx?=M2rCNWlEPTB;MD6xPEDPxE1?NGqzS40zPDF3M{KwOi=>
MCF-7NFj2blRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlXTNUDPxE1?Mn;qO|IhcA>?NUnlcldqTE2VTx?=NWTkcJpzUUN3ME2wMlE{KM7:TR?=M4C0N|I1OTV|MkC2
MCF10ANWD2W4Z6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVnod|VtOSEQvF2=MojIO|IhcA>?MWLEUXNQM4OyfWlEPTB;MD6yPUDPxE1?NF\ib5IzPDF3M{KwOi=>
HEK-293NVGzfZQ{U2mwYYPlJGF{e2G7MUmyJIFv\CB{MDFOwG0>M4PDRlIhcA>?M{GwOWROW09?MnXyTY5pcWKrdIOgR4hVNUxiYXP0bZZqfHlid3n0bEBKSzVyIH;mJFkhdk1iNYi0cXJrOjN3NEC3PVA>
Calu6NXHETmZVTnWwY4Tpc44hSXO|YYm=MYqxNEDPxE1?MlnMNVghcA>?NF3VXFNFVVORMX3TbYdvcW[rY3HueIx6KGGlY4XteYxifGW|IH\yZZRigGmwIIDy[YN2enOxch?=NWn1PJBzOjN3ME[0PFY>
IFN-gamma-induced RAW264.7M3j0OmZ2dmO2aX;uJGF{e2G7NIDid4ZFVVORNX\6cYxvUW6qaXLpeJMhdmm2cnnjJI95cWSnIIDyc4R2[3Srb36ge4l1cCCLQ{WwJI9nKDBwMEe3JO69VQ>?M4qwbFIzOjd5Mke3
IPC227FNVHuPJBXS3m2b4TvfIlkKEG|c3H5NEHJbFgyKM7:TR?=MoTGOFghcA>?NYrBTlVWTE2VTx?=M2K5OGlEPTB;MD6wO|ch|ryPNULueJVxOjF7MkS1Nlg>
Hepa-1c1c7MVrGeY5kfGmxbjDBd5NigQ>?MmPaNlUh|ryPM{S4NVYhcA>?MXvEUXNQM2HFc2lv[3KnYYPld{BPemZ{IIDyc5RmcW5ibHX2[Yw>NY\oZ4RHOjB|OUK1OFQ>
COS-7M4DZWmN6fG:2b4jpZ{BCe3OjeR?=MnvPNVAh|ryPMYnEUXNQNV[zVWVjUUN3MEyxNEDPxE1?NXKyXZBEOThyOEiwPVc>
HuH-7M4Hwd2N6fG:2b4jpZ{BCe3OjeR?=NGr0VWEyOCEQvF2=NU\J[W1lTE2VTx?=MVXJR|UxRDFyIN88US=>NI\PdJAyQDB6OEC5Oy=>
OCI-Ly3NG\wNotHfW6ldHnvckBCe3OjeR?=NEPKco4yOCEQvF5CpC=>NFT3UI01KGh?NXTtRVJwTE2VTx?=NY\SOYltUW6mdXPld{BpfW2jbjDJb4FxeGGEYXzwbIEhe3SjYnnsbZpifGmxbjD3bZRpKEWFNUCgc4YhOSEQvF2=M3fRR|E5ODJ2MUGz
A2780 cDDPMW\BdI9xfG:|aYOgRZN{[Xl?M4jZWlI1KGh?MoPQSG1UVw>?MUTJcoR2[2W|IHHwc5B1d3OrczDifUBqdmirYnn0bY5oKFCWRV6g[IVoemGmYYTpc44>NYPWc3JbOTd4OESwNVg>
LPS-stimulated RAW264.7 cellsMorKSpVv[3Srb36gRZN{[Xl?M3;kUGROW09?M2nVNGlvcGmkaYTzJG5HNWujcIDhRkBFVkFiYnnu[Ilv\w>?M1fTRVE4PDB5Mke3
PC12NYfwd|l{TnWwY4Tpc44hSXO|YYm=NFPPPYEyODBizszNxsA>NH\ZSnEzPCCqNH\ENJFFVVORMYHJcohq[mm2czC2MW9JTEFvIHHu[EBJOk9{LXnu[JVk\WRiY4n0c5RwgGmlaYT5NY\DeHNoOTdzNUi0OVQ>
PC3NXfJfZhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEHoRWozOCEQvF2=MW[0PEBpMmXRSG1UVw>?MW\JR|UxRTBwNjFOwG0>NUnWS5VZOTZ4OE[1N|c>
LP-1NVXwZ2NkSXCxcITvd4l{KEG|c3H5MUKzNFAhdk1?MXGyOEBpMWPEUXNQMlq3TY5lfWOnczDhdI9xfG:|aYOgZpkhcW6lcnXhd4lv\yClbHXheoVlKFCDUmCgcIV3\WxiYX7kJJJm\HWlaX7nJG1kdC1zIIDyc5RmcW5ibHX2[Yw>Mo\mNVU6PTh3OEm=
ES6M{mx[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWfJR|UxRTBwMEGzNFYh|ryPMkXoV2FPT0WU
A101DMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF\uUo5KSzVyPUCuNFMzPzlizszNNFy4bW1USU6JRWK=
OCUB-MM{OyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYrJR|UxRTBwMEO3N|ch|ryPNWrNZWd4W0GQR1XS
LB2518-MELMWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnTNTWM2OD1yLkCzO|Yh|ryPNUjYS5A2W0GQR1XS
SH-4NF35dXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVHHUZlVUUN3ME2wMlA1OzFizszNMmXmV2FPT0WU
KNS-42MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MorUTWM2OD1yLkC0OFQyKM7:TR?=NFHLcGdUSU6JRWK=
DSH1MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVTJR|UxRTBwMEWyPFkh|ryPMl7OV2FPT0WU
NTERA-S-cl-D1Ml7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M17B[mlEPTB;MD6wOVc4OiEQvF2=NFvHPWJUSU6JRWK=
D-542MGMUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWjJR|UxRTBwMEW5OVch|ryPMXrTRW5ITVJ?
KS-1MmT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWDJR|UxRTBwME[0OVgh|ryPNY[0W3VLW0GQR1XS
BL-41Mn7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYXJR|UxRTBwME[5OFch|ryPM3TJR3NCVkeHUh?=
LXF-289NVfPbZZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3nzbmlEPTB;MD6wO|A3PiEQvF2=NI[2eItUSU6JRWK=
D-247MGM1jTd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MljZTWM2OD1yLkC3NlA6KM7:TR?=M1HzVHNCVkeHUh?=
MMAC-SFMniwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFTGcG1KSzVyPUCuNFczPjhizszNMnXCV2FPT0WU
CP66-MELM2X4cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlP5TWM2OD1yLkC3OUDPxE1?M13uVnNCVkeHUh?=
LB771-HNCMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX\JR|UxRTBwMEiwN|Yh|ryPMVfTRW5ITVJ?
no-10NUnNOZFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRTBwMEi5NFkh|ryPM2DuTnNCVkeHUh?=
A388M3;pcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVHzOIZwUUN3ME2wMlA6ODZ3IN88US=>NFjuOYlUSU6JRWK=
OPM-2Ml\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXy3VY5kUUN3ME2wMlExPDd2IN88US=>M2PsZ3NCVkeHUh?=
OVCAR-4NHHNZmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnPpTWM2OD1yLkGwPVM5KM7:TR?=NEfGVVNUSU6JRWK=
HOP-62NXHjclJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWfJR|UxRTBwMUC5OFkh|ryPMWnTRW5ITVJ?
ML-2NGP2fJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX:xXFdrUUN3ME2wMlEyQDB4IN88US=>NEDWPGJUSU6JRWK=
UACC-257M3\5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYrkVG1bUUN3ME2wMlEyQTJ5IN88US=>MV;TRW5ITVJ?
NEC8M{Xoc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M136b2lEPTB;MD6xNVk6PSEQvF2=MnTrV2FPT0WU
ONS-76NXroXmlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXW3O4hrUUN3ME2wMlEzQTN3IN88US=>NH7K[otUSU6JRWK=
KE-37MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlnvTWM2OD1yLkGzNlc5KM7:TR?=M3TneHNCVkeHUh?=
HT-144NYPOVYEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWLJR|UxRTBwMUO4PVUh|ryPNGjITIdUSU6JRWK=
LB2241-RCCM1jGdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml;UTWM2OD1yLkG0NlQ4KM7:TR?=NWHXbHhpW0GQR1XS
TE-5M2PoTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mo\nTWM2OD1yLkG0Nlc5KM7:TR?=MoXoV2FPT0WU
KINGS-1NE\abphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX7JR|UxRTBwMUS3PUDPxE1?NYnVSoVWW0GQR1XS
NCI-H69MkTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXraU3hoUUN3ME2wMlE2OTRzIN88US=>NV7qN3Y2W0GQR1XS
CAS-1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFLPUmlKSzVyPUCuNVU1QDJizszNNETY[3NUSU6JRWK=
D-263MGM3v1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTBwMU[wNFYh|ryPNXjONoZFW0GQR1XS
A253MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFzm[3pKSzVyPUCuNVYyOjhizszNNIPKfZhUSU6JRWK=
PF-382Mkj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4T2eGlEPTB;MD6xOlcxPiEQvF2=NHfW[3ZUSU6JRWK=
CESSM1PNcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWC4VpZTUUN3ME2wMlE4ODZizszNMmn3V2FPT0WU
MZ2-MELM4\6Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn;uTWM2OD1yLkG3OVU6KM7:TR?=MWLTRW5ITVJ?
HELNYDxWY9rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVfJR|UxRTBwMUi1NVch|ryPNWHpd|hxW0GQR1XS
D-392MGNFPO[HZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1eyc2lEPTB;MD6xPVEyPSEQvF2=Mn3rV2FPT0WU
SK-LMS-1M1rnfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV;JR|UxRTBwMUmzNFMh|ryPNX;EcnNrW0GQR1XS
GI-ME-NMkP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXfDc5hTUUN3ME2wMlE6OzB4IN88US=>NHfacVZUSU6JRWK=
LB831-BLCNU[4NZhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWHueoVLUUN3ME2wMlE6OzRizszNM{TtcnNCVkeHUh?=
DU-4475M3\pR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mlj2TWM2OD1yLkG5OlU5KM7:TR?=M2\HTnNCVkeHUh?=
IST-SL1NFP2S3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3HpN2lEPTB;MD6yNFA6PCEQvF2=Mm[0V2FPT0WU
GAKMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkDITWM2OD1yLkKwOVM1KM7:TR?=MWDTRW5ITVJ?
EW-1NHe1dG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MorvTWM2OD1yLkKxNFQ4KM7:TR?=NUixU2ZoW0GQR1XS
LAMA-84M1LicGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIT3WHJKSzVyPUCuNlE5PTFizszNM4\JUnNCVkeHUh?=
SK-UT-1NUD6SZpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGTVRWlKSzVyPUCuNlIxPDlizszNNVPEO4pwW0GQR1XS
VA-ES-BJMmDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkO0TWM2OD1yLkKyNlU4KM7:TR?=M{H1PXNCVkeHUh?=
ACNMkXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV\Je3J{UUN3ME2wMlIzPjN6IN88US=>NFKzR3ZUSU6JRWK=
SK-PN-DWNFLkfWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHrSNXVKSzVyPUCuNlMyQSEQvF2=NX\zVIQxW0GQR1XS
HD-MY-ZMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV3JR|UxRTBwMkOzNFMh|ryPM2XGOnNCVkeHUh?=
LB373-MEL-DMWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX7sW3F3UUN3ME2wMlI1OTl6IN88US=>M4PVRXNCVkeHUh?=
COLO-829MnTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGX1PW5KSzVyPUCuNlQzPTdizszNNEHaXVdUSU6JRWK=
ES8M4O5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV3nTWNEUUN3ME2wMlI1PzZ|IN88US=>NV2yUop1W0GQR1XS
RXF393MlTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV63V5c{UUN3ME2wMlI2ODF3IN88US=>M4jqUXNCVkeHUh?=
TK10NIDVXWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlfMTWM2OD1yLkK1OFM2KM7:TR?=MlPMV2FPT0WU
LOUCYMkfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1r6ZmlEPTB;MD6yOVQ2PiEQvF2=M{jJ[3NCVkeHUh?=
MZ7-melM2r6W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGLpVoZKSzVyPUCuNlY{PzRizszNNF31XZpUSU6JRWK=
CP67-MELMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUTJR|UxRTBwMk[3N{DPxE1?MWHTRW5ITVJ?
C2BBe1M2Pk[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlLPTWM2OD1yLkK3PVA4KM7:TR?=Ml7MV2FPT0WU
K052M4L6XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWrJR|UxRTBwMki5PUDPxE1?MV3TRW5ITVJ?
MOLT-16NEDLR|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVrBXVExUUN3ME2wMlI6PTJ2IN88US=>MnLOV2FPT0WU
KNS-81-FDNH3jTHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkjPTWM2OD1yLkOwN|I{KM7:TR?=MlT4V2FPT0WU
CMKMmPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYTJR|UxRTBwM{GxNkDPxE1?MnPyV2FPT0WU
LAN-6MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYfJR|UxRTBwM{GzJO69VQ>?MVXTRW5ITVJ?
KLEMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIrnUVRKSzVyPUCuN|E{ODZizszNNF\5OIJUSU6JRWK=
NCCITMnzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkHWTWM2OD1yLkOxO|g{KM7:TR?=MVHTRW5ITVJ?
HHNIDmTVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVHlWlN1UUN3ME2wMlMzQDl5IN88US=>MoTiV2FPT0WU
TE-8MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGKxWmdKSzVyPUCuN|QzPzlizszNMW\TRW5ITVJ?
GDM-1MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXLJR|UxRTBwM{WxNFQh|ryPNGHoW2tUSU6JRWK=
NCI-H747MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVv3PZdnUUN3ME2wMlM4OTB|IN88US=>NIHhXVdUSU6JRWK=
NCI-H1092NGfOTY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MknSTWM2OD1yLkO4PFQ1KM7:TR?=M1zQWHNCVkeHUh?=
8-MG-BANUDUOnkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX7JR|UxRTBwM{m4N|ch|ryPNVrYTWpiW0GQR1XS
NB17NHPwSoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX7BVGN1UUN3ME2wMlQzQTdizszNMXzTRW5ITVJ?
LC4-1MnnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlHtTWM2OD1yLkSzOlA4KM7:TR?=MoXTV2FPT0WU
TE-1MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWHJR|UxRTBwNEWxNVkh|ryPMYXTRW5ITVJ?
KALS-1M2GxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVrJR|UxRTBwNE[1PFQh|ryPNYrQWpV6W0GQR1XS
CCRF-CEMNYX3WYZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIi5SYpKSzVyPUCuOFc3PzRizszNMXPTRW5ITVJ?
OS-RC-2NXjZNGtyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnPzTWM2OD1yLkS3PVczKM7:TR?=MVTTRW5ITVJ?
A704NUOwUIsyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWHJR|UxRTBwNEi2PVIh|ryPNFi3fFlUSU6JRWK=
BB49-HNCMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXTZeYc1UUN3ME2wMlQ6ODl4IN88US=>MXHTRW5ITVJ?
EVSA-TM1HJUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYXWe4s5UUN3ME2wMlQ6QTFzIN88US=>NYPSeY9PW0GQR1XS
Mo-TMkfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoHRTWM2OD1yLkWxO|YzKM7:TR?=NY\NWIoxW0GQR1XS
MONO-MAC-6MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIfRU2xKSzVyPUCuOVM3OTFizszNMoSyV2FPT0WU
BB65-RCCNHrKO25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVPJR|UxRTBwNU[4NVEh|ryPMlX1V2FPT0WU
NCI-H1882NWTXblROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVzJR|UxRTBwNUmwN|Yh|ryPMYXTRW5ITVJ?
TE-9NXvEVnZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkXPTWM2OD1yLk[xNFM{KM7:TR?=NF74OmVUSU6JRWK=
NCI-H2126NWDCRmpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYTMSGtrUUN3ME2wMlYzPjZ7IN88US=>NYDpeIk2W0GQR1XS
SF268MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTBwNkW2OFEh|ryPM2r2ZnNCVkeHUh?=
SW872M2\0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX3pdYd1UUN3ME2wMlY2PzJ7IN88US=>NFHwNpdUSU6JRWK=
LS-513MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M13HdGlEPTB;MD62Olc2OSEQvF2=M1T6XHNCVkeHUh?=
NCI-H1355MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGHuWmNKSzVyPUCuOlg3OTlizszNM1H4[3NCVkeHUh?=
BL-70NF3NepVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml[wTWM2OD1yLk[5N|g5KM7:TR?=NUTCZWNYW0GQR1XS
NCI-SNU-5Ml\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXfJR|UxRTBwNkm1OFUh|ryPM4HsV3NCVkeHUh?=
SNU-C2BMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX\JR|UxRTBwN{C3N|kh|ryPNVm5RnR2W0GQR1XS
GB-1Moe4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXLPdHBmUUN3ME2wMlczOTJ2IN88US=>NVG4NHg6W0GQR1XS
CTB-1Mk\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVrJ[2VDUUN3ME2wMlc4QTV3IN88US=>Mkn2V2FPT0WU
BeckerNX;DfoZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRTBwN{m2NlEh|ryPNVH0bJNjW0GQR1XS
KM12M3nDOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWDnfW9wUUN3ME2wMlg2PDZ4IN88US=>MUDTRW5ITVJ?
ES7NF;lb|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4jNTWlEPTB;MD64PVY2KM7:TR?=MXvTRW5ITVJ?
COLO-684MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoTVTWM2OD1yLkmwOlU5KM7:TR?=MXXTRW5ITVJ?
HCC2998NYj3NoQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUjJR|UxRTBwOUO4OVQh|ryPM4ToRnNCVkeHUh?=
TE-10NVLrOZZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MorOTWM2OD1yLkm2OFMh|ryPMkfrV2FPT0WU
SF126NG\OV21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlX0TWM2OD1yLkm4PVcyKM7:TR?=MnLvV2FPT0WU
EKVXM3TxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkXnTWM2OD1zLkCzOFQzKM7:TR?=MUPTRW5ITVJ?
KARPAS-45MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUjJR|UxRTFwMESwNVYh|ryPM2PneXNCVkeHUh?=
KGNM1rPXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIHKV2tKSzVyPUGuNFUxPDVizszNNUWzS|c{W0GQR1XS
ES1M{TURWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWnJR|UxRTFwMEe5NlEh|ryPMlu1V2FPT0WU
L-540MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkfhTWM2OD1zLkGxPFM6KM7:TR?=MUfTRW5ITVJ?
KURAMOCHIM{DRN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NW\JXoRnUUN3ME2xMlEzOzd2IN88US=>Mn7lV2FPT0WU
LU-65NFfHO4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWLJR|UxRTFwMUK3OVMh|ryPNX3tRW57W0GQR1XS
MFH-inoM3PHRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWHsO|JJUUN3ME2xMlE4PTBzIN88US=>NXrzNZdIW0GQR1XS
NCI-H23NGjudFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUTJR|UxRTFwMkC0NUDPxE1?NFHjWGZUSU6JRWK=
IA-LMM3H1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1TOcWlEPTB;MT6yOFEyPiEQvF2=NXP6epBPW0GQR1XS
PSN1MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEjrfFNKSzVyPUGuNlcxOTZizszNNYL3bVh6W0GQR1XS
NCI-H719M2jafmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHThe4xKSzVyPUGuNlc1OTFizszNM1fT[HNCVkeHUh?=
SW684MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYHJR|UxRTFwMki2OVkh|ryPMUPTRW5ITVJ?
HCE-4NW\jV2tuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1K4XGlEPTB;MT6zNFIzOSEQvF2=NXP5b4JEW0GQR1XS
EW-16NXXkW21GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3zSTWlEPTB;MT6zNVM1PyEQvF2=NYTwOmtXW0GQR1XS
NCI-H128M3jCXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlfQTWM2OD1zLkO1PFE1KM7:TR?=MlfjV2FPT0WU
HC-1NIrCO2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUfJR|UxRTFwM{ixO{DPxE1?MoT3V2FPT0WU
IST-MES1NFTlVoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnTNTWM2OD1zLkSwNlA5KM7:TR?=MVnTRW5ITVJ?
RajiNEDzbXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3fUd2lEPTB;MT60NVg2KM7:TR?=MV\TRW5ITVJ?
DMS-114M4nBPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRTFwNES1N|kh|ryPMnPIV2FPT0WU
GI-1NWO1NY5JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGrVXmJKSzVyPUGuOFcyOzFizszNMlmzV2FPT0WU
NCI-H2081NHPvZm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF3C[otKSzVyPUGuOVUyQTZizszNMVnTRW5ITVJ?
LC-1FNV7NTHZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUPJR|UxRTFwNUWxPVgh|ryPM{H6ZXNCVkeHUh?=
NCI-H2227MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV;U[IE4UUN3ME2xMlYyPTZzIN88US=>Mor0V2FPT0WU
D-502MGM3G4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIjWPXBKSzVyPUGuOlczOTFizszNMo\OV2FPT0WU
NCI-H2141NVjpd5lFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH7YOYlKSzVyPUGuOlc{OTdizszNNH63VWxUSU6JRWK=
LS-411NMlLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXLJWlZZUUN3ME2xMlY6QDB5IN88US=>M1:wXHNCVkeHUh?=
SU-DHL-1M2XON2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVqwS4RjUUN3ME2xMlcyOjhzIN88US=>NVTybXBpW0GQR1XS
BB30-HNCMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYj3[3p2UUN3ME2xMlczPjh3IN88US=>M3zXeHNCVkeHUh?=
TE-15NUe0O21YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3;h[GlEPTB;MT65NlM4OyEQvF2=MlX0V2FPT0WU
JVM-3MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2jjOmlEPTB;MT65N|kxPCEQvF2=MkjDV2FPT0WU
IST-SL2M1fRVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3PW[2lEPTB;Mj6wNVI2OiEQvF2=MlfuV2FPT0WU
EW-18M{XoNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTJwMEKzN|ch|ryPNIW5NoVUSU6JRWK=
DJM-1NUHpcXZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\tSHhLUUN3ME2yMlAzPTV{IN88US=>NHz5WHlUSU6JRWK=
no-11NWP2bVlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXHJR|UxRTJwMEOxNFQh|ryPM1TtcnNCVkeHUh?=
QIMR-WILMYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn;KTWM2OD1{LkG2O|YzKM7:TR?=Ml3jV2FPT0WU
MC-CARM1TUVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH3idmlKSzVyPUKuNlI6PSEQvF2=NYP4Wmg5W0GQR1XS
KM-H2MnPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUHvVIJFUUN3ME2yMlI6ODR|IN88US=>M2XTZ3NCVkeHUh?=
ECC12Mn3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3n6fWlEPTB;Mj6zO|k1KM7:TR?=MlnDV2FPT0WU
HCE-TNWDjb|R3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXLZXYIzUUN3ME2yMlQ1QDh|IN88US=>NYXlfpE{W0GQR1XS
MFM-223NWnJWlFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF\yUpdKSzVyPUKuOVA5PzFizszNMoDwV2FPT0WU
SW982MmXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4HoRWlEPTB;Mj61NVQ5KM7:TR?=MXjTRW5ITVJ?
KG-1MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmDPTWM2OD1{Lki4O|kyKM7:TR?=M3PjfnNCVkeHUh?=
ES4MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGXwOpNKSzVyPUOuNFYyOTFizszNMmLoV2FPT0WU
SCC-3MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUfQPWZPUUN3ME2zMlExQDR6IN88US=>NWXWSI5NW0GQR1XS
RH-1NELkRZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2nyXGlEPTB;Mz6zPFc1QCEQvF2=Mn25V2FPT0WU
NCI-H748MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTNwNESyOlYh|ryPNUHlPXNbW0GQR1XS
HCC2218NHvDT3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXXDbpRxUUN3ME2zMlQ3QTN5IN88US=>Mn7YV2FPT0WU
MEG-01MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{PBe2lEPTB;Mz61PVY5KM7:TR?=NILMNnRUSU6JRWK=
NB12M1jvUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4\McWlEPTB;Mz61PVg5QCEQvF2=M3LoSHNCVkeHUh?=
SNB75NFfxdWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFmyXG1KSzVyPUOuOlAyODNizszNMl3HV2FPT0WU
KMS-12-PEM3q0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1XVRmlEPTB;Mz62O|czOyEQvF2=MYPTRW5ITVJ?
SKM-1MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUDJR|UxRTNwN{GzO|Yh|ryPMlTCV2FPT0WU
COLO-320-HSRNH7kclJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTNwN{W2N|Qh|ryPMXzTRW5ITVJ?
NKM-1NHTs[GJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mmm4TWM2OD1|Lke3N|c5KM7:TR?=MUXTRW5ITVJ?
TE-6MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWHpS2J{UUN3ME2zMlk1PTZzIN88US=>M{nJfHNCVkeHUh?=
D-336MGMmO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnjtTWM2OD12LkCxNVY3KM7:TR?=M1X3WnNCVkeHUh?=
NCI-H1650MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV3JR|UxRTRwMUW3PVch|ryPNVPNcnR7W0GQR1XS
ES3M3rtbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M37qWWlEPTB;ND6zNlgzPCEQvF2=MYfTRW5ITVJ?
YTNX\pTHVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{nhTGlEPTB;ND6zOVQzPCEQvF2=NXywNWFwW0GQR1XS
ES5NI\xWoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnL1TWM2OD12LkSwNlU2KM7:TR?=NY\SNXE1W0GQR1XS
LB647-SCLCNH6zW3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH[2[ZFKSzVyPUSuOVY{ODhizszNM1Ll[nNCVkeHUh?=
HAL-01MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3eyVmlEPTB;ND61O|A{PCEQvF2=NHLme3dUSU6JRWK=
LP-1NH[4TIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTRwN{KzO|Eh|ryPNFTEe41USU6JRWK=
BC-1M3XMTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFm0fmlKSzVyPUWuNFA1PDdizszNMXLTRW5ITVJ?
EB-3NWfhVnpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2jWT2lEPTB;NT6wN|A1OSEQvF2=NWrOSZZUW0GQR1XS
GT3TKBMorqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUCzT5RTUUN3ME21MlE4PjZ{IN88US=>MWTTRW5ITVJ?
NCI-H209M{j4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFX0[Y1KSzVyPUWuNVk{PTJizszNMkTNV2FPT0WU
BT-474MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXXVdFRRUUN3ME21MlI{OTB{IN88US=>M{TsfXNCVkeHUh?=
RKOM4DiN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4XafWlEPTB;NT6yN|QzOiEQvF2=NH\pZm1USU6JRWK=
SIMANYe3WmtrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWj1W5Z5UUN3ME21MlMxPzZ3IN88US=>NUPpSoFtW0GQR1XS
RLNEm5d|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVfJR|UxRTVwM{e1OFEh|ryPNUHzfGM3W0GQR1XS
GCIYM2nEbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXO2R2V1UUN3ME21MlQ4OjN4IN88US=>MYTTRW5ITVJ?
Calu-6NVzX[mJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVnJR|UxRTVwNkKyJO69VQ>?NH\vcYdUSU6JRWK=
ALL-POMmraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1PKU2lEPTB;NT62N|c6PSEQvF2=MVHTRW5ITVJ?
ARH-77M1rWemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXLJR|UxRTVwNkewPFch|ryPM1Xsc3NCVkeHUh?=
A4-FukMnK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml7VTWM2OD14LkC4NVE5KM7:TR?=Mn;sV2FPT0WU
NCI-H1581MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlK4TWM2OD14LkKzPFQ6KM7:TR?=MlzhV2FPT0WU
HUTU-80NXLsPIhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NELIe4ZKSzVyPU[uN|Y5QTdizszNM2K4WXNCVkeHUh?=
TGWMki5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX3JR|UxRTZwNEW1PVMh|ryPM3XQWHNCVkeHUh?=
SK-N-FIM1PvbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVLJR|UxRTZwNEW4OVQh|ryPMlTOV2FPT0WU
U-266M1ewRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHLkSW5KSzVyPU[uOVE6OjZizszNMWDTRW5ITVJ?
EM-2NFrjSJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnHkTWM2OD14Lk[3NFk6KM7:TR?=NGGzcYdUSU6JRWK=
NMC-G1M{\aUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{nmO2lEPTB;Nj63NVg6PSEQvF2=M2SzeHNCVkeHUh?=
KASUMI-1NEjjdo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVTUNpNPUUN3ME22Mlg1Pzh5IN88US=>NXnDfVY5W0GQR1XS
NALM-6MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{f6e2lEPTB;Nj64Olc2PCEQvF2=NUXvXY5zW0GQR1XS
OCI-AML2MlvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVvJR|UxRTdwMECzNlYh|ryPMknUV2FPT0WU
SHP-77MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFLqPFNKSzVyPUeuNlI1OyEQvF2=MYrTRW5ITVJ?
NOMO-1NF3Sd2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3r2RmlEPTB;Nz6yOFI2PCEQvF2=MlTRV2FPT0WU
SK-N-DZM4nzb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRTdwN{GwPFkh|ryPNYXRW5IzW0GQR1XS
LB1047-RCCNV7wc4U{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUDRSW5wUUN3ME23MlczOjNzIN88US=>NGrsSFdUSU6JRWK=
MZ1-PCNUXCcnVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXPJR|UxRTdwOE[1OVgh|ryPNULnXldlW0GQR1XS
NB10MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEnY[WhKSzVyPUeuPVk2PTZizszNNWLXbHRVW0GQR1XS
RL95-2MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXvxe4JRUUN3ME24MlExQDR{IN88US=>NGDobWRUSU6JRWK=
OMC-1Mor2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml\UTWM2OD16LkWyNVkyKM7:TR?=NV\jfHFvW0GQR1XS
D-283MEDMoq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkPiTWM2OD16LkmxO|E6KM7:TR?=NYT2eYs4W0GQR1XS
MC116MnyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3;zSmlEPTB;OD65O|k1KM7:TR?=M{Tyb3NCVkeHUh?=
SJSA-1NGTSOmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXP2NFRRUUN3ME25MlA6ODlzIN88US=>NXnRTmVKW0GQR1XS
JiyoyeP-2003MlLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnrGTWM2OD17LkK5N|E4KM7:TR?=MoXSV2FPT0WU
IST-MEL1MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWrJR|UxRTlwN{SxPVgh|ryPM3OxS3NCVkeHUh?=
CTV-1NXO3PIpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYLCVoFSUUN3ME2xNE4xQTd7IN88US=>NXfZfYdUW0GQR1XS
NH-12NIjFN3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX[zNZdJUUN3ME2xNE4zPDN|IN88US=>NID0OYxUSU6JRWK=
CA46MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2\RUGlEPTB;MUCuN|YyKM7:TR?=M{jzdXNCVkeHUh?=
NCI-SNU-1NUTDZpVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVTNZnQxUUN3ME2xNE41QTZ7IN88US=>Mnf4V2FPT0WU
SCLC-21HM1fEeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUHwbppCUUN3ME2xNE43PTl4IN88US=>MWTTRW5ITVJ?
EC-GI-10MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGLzT4hKSzVyPUGwMlcxOzFizszNNEfESXlUSU6JRWK=
SRNV7RPGJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWezc4tlUUN3ME2xNU4xOTh3IN88US=>MmrtV2FPT0WU
NCI-H1648M2n2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\FTWM2OD1zMT6wPVY2KM7:TR?=NELuZ|VUSU6JRWK=
TGBC1TKBMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWW3cFlLUUN3ME2xNU41OTB{IN88US=>M4jLcXNCVkeHUh?=
EW-11NVrtbHpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG\MXpRKSzVyPUGxMlUyQDZizszNMV\TRW5ITVJ?
SK-MM-2MkLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGPVUnNKSzVyPUGxMlgxPjFizszNNUXQbWl4W0GQR1XS
NCI-H524NHS5[3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYT5dXZpUUN3ME2xNU46QDJ{IN88US=>NH;3RYhUSU6JRWK=
NOS-1Mn;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXrIe4t{UUN3ME2xNk4xOzR3IN88US=>MWLTRW5ITVJ?
AM-38NXvYOXU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYjJR|UxRTF{LkW2N|Mh|ryPMX3TRW5ITVJ?
A498NVn0OGNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{LuXmlEPTB;MUKuO|A3QSEQvF2=M17Mb3NCVkeHUh?=
KARPAS-422MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M13nVGlEPTB;MUKuO|Q6PiEQvF2=NVfncJlrW0GQR1XS
LU-139MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFqycVlKSzVyPUGyMlkxOjZizszNNVz4NJVGW0GQR1XS
COR-L88MnzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV3JR|UxRTF{LkmzPFIh|ryPM2jvTHNCVkeHUh?=
K5Moi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVLmdZdoUUN3ME2xNk46PDZ{IN88US=>Mle2V2FPT0WU
NB13MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{PCdGlEPTB;MUKuPVc5OyEQvF2=MkTEV2FPT0WU
MRK-nu-1MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYTJR|UxRTF|LkG5OUDPxE1?MVzTRW5ITVJ?
MHH-NB-11NHnRe2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHTPSZBKSzVyPUGzMlI6ODJizszNMlLlV2FPT0WU
KU812NWjSRYVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2DwW2lEPTB;MUOuOlEzPCEQvF2=MnvvV2FPT0WU
TE-12M3i5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NELOXVlKSzVyPUGzMlY6QTRizszNM1;J[XNCVkeHUh?=
NCI-N87MmroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYfJR|UxRTF|LkezOkDPxE1?M2Dm[XNCVkeHUh?=
EB2Mlr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MorwTWM2OD1zMz64OVA2KM7:TR?=M4r2cXNCVkeHUh?=
DBM{XBc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTF|Lkm4PFUh|ryPMlOwV2FPT0WU
697NV7abno2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEftWG9KSzVyPUG0MlQ2OTFizszNNEnFXXZUSU6JRWK=
MSTO-211HNVPFO|YzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWXJR|UxRTF2Lke0OFgh|ryPM4PzT3NCVkeHUh?=
JVM-2NYnw[Hd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmTiTWM2OD1zND63O|M2KM7:TR?=MmOxV2FPT0WU
COLO-824NEDpZXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlPtTWM2OD1zND63PVk1KM7:TR?=NHjtcndUSU6JRWK=
BC-3M4jBOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTF3LkO5PEDPxE1?Mo\QV2FPT0WU
BOKUMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWrJR|UxRTF3Lkm2NFgh|ryPMmnVV2FPT0WU
GOTONUW1NZB6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGjVd|RKSzVyPUG2Mlk3OTdizszNMl;2V2FPT0WU
HCC2157M4\pO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF7BOHJKSzVyPUG3MlQ4PTVizszNMYDTRW5ITVJ?
LS-1034NVq3OlM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVPJR|UxRTF5Lk[4NVgh|ryPNFPoZYFUSU6JRWK=
CAL-148NYLuZXRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFj3SXVKSzVyPUG3Mlk4QTZizszNNFjOWWRUSU6JRWK=
MOLT-4M17NeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTF6LkiyNFgh|ryPMUPTRW5ITVJ?
DaudiMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWq0fnNiUUN3ME2xPE46OjNzIN88US=>M{PDUnNCVkeHUh?=
J-RT3-T3-5NGfvTFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4HkSWlEPTB;MUmuOFA3PiEQvF2=NWnQTIxjW0GQR1XS
KMOE-2Mom5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3m4WWlEPTB;MUmuOlQ5OiEQvF2=NFrLO5NUSU6JRWK=
HL-60NELBcpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVjJR|UxRTJyLkG5OlUh|ryPNIDacWhUSU6JRWK=
P31-FUJNFHTNGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3\CR2lEPTB;MkCuOFc2OyEQvF2=NHXFR2FUSU6JRWK=
IM-9M33pUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mo\5TWM2OD1{MD62NlI1KM7:TR?=NIewXWFUSU6JRWK=
HDLM-2NFOxdXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIDRT4NKSzVyPUKwMlg5OjFizszNMkjiV2FPT0WU
NCI-H1304MlvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYf2U5lQUUN3ME2yNU4xOzFzIN88US=>M33KbHNCVkeHUh?=
NCI-H345NVjDNYVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M13sWGlEPTB;MkGuNFY1OyEQvF2=M4Dz[nNCVkeHUh?=
RPMI-6666MnK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NILDbHFKSzVyPUKxMlM3ODJizszNMUfTRW5ITVJ?
GR-STMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4DjRWlEPTB;MkGuOFE4KM7:TR?=MWHTRW5ITVJ?
CHP-126M3j0[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWDJR|UxRTJzLk[xPFEh|ryPMXXTRW5ITVJ?
EHEBNGHmelZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmPNTWM2OD1{MT62O|MyKM7:TR?=NWHO[lF1W0GQR1XS
CPC-NM1jPfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWfoOmxzUUN3ME2yOE4xOjBzIN88US=>M4HWOnNCVkeHUh?=
NB1NXfiVHl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnnGTWM2OD1{ND62PVM6KM7:TR?=NVfDcJVDW0GQR1XS
LS-123NWfEN2hQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYLJR|UxRTJ2LkmwNVIh|ryPMkD3V2FPT0WU
ST486M1nscWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnvETWM2OD1{NT6xNVE{KM7:TR?=NYfvW4JuW0GQR1XS
NCI-H1963NHLRWZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M37U[GlEPTB;Mk[uNFYzOyEQvF2=NVu3V4QxW0GQR1XS
U-87-MGNHTXXWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmnOTWM2OD1{Nj63OlQ1KM7:TR?=MWLTRW5ITVJ?
COR-L279MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV64cYYxUUN3ME2yOk44QTJ{IN88US=>NGLCUmZUSU6JRWK=
LU-165M4jlNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1fMTmlEPTB;MkiuNFg3OSEQvF2=M2Wzb3NCVkeHUh?=
COLO-800MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFPZOmFKSzVyPUK4MlI6PTZizszNMkXiV2FPT0WU
ETK-1MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3HDSWlEPTB;MkiuN|Q1PiEQvF2=MoLCV2FPT0WU
LNCaP-Clone-FGCNWDXPGRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnTCTWM2OD1{OT65NlgyKM7:TR?=MlPkV2FPT0WU
SIG-M5M3HLV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYPaZVJIUUN3ME2zNE44QTV{IN88US=>NEGzUmVUSU6JRWK=
NB6Moj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NID3[ZhKSzVyPUOwMlk2ODNizszNMW\TRW5ITVJ?
NCI-H2107M3jw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoXkTWM2OD1|MT6yN|M5KM7:TR?=M{XBS3NCVkeHUh?=
SNU-C1M2nxVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MU\JR|UxRTNzLkOxNlYh|ryPNYewd4w4W0GQR1XS
JARM17wXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHHDN|ZKSzVyPUOxMlM4QTlizszNNITJeoNUSU6JRWK=
L-363NH\JXWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUXJR|UxRTN{LkKxOFQh|ryPNVzH[IJiW0GQR1XS
EW-24MnTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{LrbGlEPTB;M{KuN|Q4PCEQvF2=NH3weJRUSU6JRWK=
NB69M2nldmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4THSmlEPTB;M{OuOlQ2PCEQvF2=NEmzVJpUSU6JRWK=
EW-13Ml7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVPJR|UxRTN|Lki5Olkh|ryPM4[5UXNCVkeHUh?=
Ramos-2G6-4C10M2HRNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUnJR|UxRTN2LkK5PVMh|ryPNIKyTHVUSU6JRWK=
TE-11M{\0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlXtTWM2OD1|ND60PFIzKM7:TR?=MUXTRW5ITVJ?
L-428MkPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3PDdmlEPTB;M{SuO|U{PiEQvF2=MV7TRW5ITVJ?
KP-N-YNM{nYR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGjibVRKSzVyPUO0MlkxPTdizszNMnvXV2FPT0WU
CGTH-W-1MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGfjfIxKSzVyPUO2MlkxPDhizszNNUfJSHJpW0GQR1XS
K-562NY\tcIhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWToO3BkUUN3ME2zO{4xQDZ2IN88US=>MWfTRW5ITVJ?
NCI-H1299NFLvdFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVTJR|UxRTN6LkG2NFMh|ryPMmGyV2FPT0WU
RCC10RGBMVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUTPNodNUUN3ME2zPE4zODh|IN88US=>M3jEUHNCVkeHUh?=
NCI-SNU-16NF\DUnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGXsSWFKSzVyPUO4MlU3PTNizszNNHvzdG1USU6JRWK=
LC-2-adMoX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlHJTWM2OD1|OT60N|M4KM7:TR?=NF31eFhUSU6JRWK=
MHH-PREB-1MmSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnnOTWM2OD1|OT63N|g5KM7:TR?=M4nzU3NCVkeHUh?=
NCI-H64M13qeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2HEc2lEPTB;NECuNFk1QCEQvF2=NWK3eW5sW0GQR1XS
LB996-RCCNFu5V5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXfIW3BqUUN3ME20NE45PzF4IN88US=>NHnzWmxUSU6JRWK=
DELNXvZNGx[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlLETWM2OD12MT60OFA2KM7:TR?=MonkV2FPT0WU
MLMAMUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2LMNWlEPTB;NEGuO|U6PSEQvF2=M3qye3NCVkeHUh?=
SBC-1M3:wXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUnaUYZMUUN3ME20Nk4yQDB4IN88US=>MXPTRW5ITVJ?
MPP-89NYTyXIljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoTJTWM2OD12Mj61PFc2KM7:TR?=MlfPV2FPT0WU
MV-4-11NHKwPFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1;VZmlEPTB;NEKuPVA3PyEQvF2=Mny3V2FPT0WU
EoL-1-Mm\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlrITWM2OD12ND6xOVY5KM7:TR?=NGnOSoNUSU6JRWK=
CW-2Ml3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUj1dpg4UUN3ME20OE45OzR{IN88US=>NEfvR5RUSU6JRWK=
HTM2XEOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4TlVGlEPTB;NEWuO|AxPyEQvF2=Ml;pV2FPT0WU
SW954NHr2eZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{TucWlEPTB;NEeuOFEzQCEQvF2=MoPGV2FPT0WU
A3-KAWNFnZRpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlHxTWM2OD12OT64NFYyKM7:TR?=MX;TRW5ITVJ?
TC-YIKMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH70UY1KSzVyPUWwMlA{PjNizszNM3fFcnNCVkeHUh?=
SW962MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NG\rZZZKSzVyPUW0Mlg{PTdizszNNI\tc2dUSU6JRWK=
KP-N-RT-BM-1NU\jdYZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYrJR|UxRTV4Lk[2N|gh|ryPNXz6fVdsW0GQR1XS
NCI-H1395NVXlcVY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWPsVFBMUUN3ME21PE45OTd{IN88US=>NHfybIpUSU6JRWK=
RPMI-8402NFO0TJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXi5NnNzUUN3ME21PE46PTJ4IN88US=>M2XSe3NCVkeHUh?=
SCHNGO2dJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml35TWM2OD14MD65OlM5KM7:TR?=NUiwNG1pW0GQR1XS
NCI-H2196NXLtUFFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYnS[IxSUUN3ME22NU4zOzFizszNNVLKNWJIW0GQR1XS
LOXIMVIMoThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4HmXmlEPTB;NkGuPFI3PiEQvF2=M{\YO3NCVkeHUh?=
TGBC24TKBNEPTWnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGToPHVKSzVyPU[yMlE1QTFizszNNIDhWphUSU6JRWK=
SK-MEL-2NEL2ZlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4i5VmlEPTB;NkOuPVg6OiEQvF2=NFO5WnBUSU6JRWK=
U-698-MNGKyXZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1jSb2lEPTB;NkiuOVY5PyEQvF2=MWrTRW5ITVJ?
NCI-H1522NXe2OFJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWLPT2F7UUN3ME22PU4xODR5IN88US=>NHjENnVUSU6JRWK=
UACC-812NUTpNmIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnTLTWM2OD14OT61NlA6KM7:TR?=Mmi4V2FPT0WU
MHH-CALL-2MmfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWPRS3FPUUN3ME23NE4xPiEQvF2=NF3JUGZUSU6JRWK=
NB5MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGKzUZdKSzVyPUewMlM1PjhizszNM133OHNCVkeHUh?=
KARPAS-299NVHmPIhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1jyN2lEPTB;N{CuOFQ1PyEQvF2=NWG5PZVkW0GQR1XS
NCI-H1694NVzybIo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWXNNYFNUUN3ME23NU4xOzJizszNNVrZRWdLW0GQR1XS
NCI-H82M3nUXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIHSRY9KSzVyPUexMlk2ODdizszNNGK3S4FUSU6JRWK=
SCC-15MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFvQUoVKSzVyPUeyMlM1KM7:TR?=M3H6SnNCVkeHUh?=
NCI-H1436MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYHk[GZMUUN3ME23Nk44PDV4IN88US=>M{DoTHNCVkeHUh?=
ATN-1NHq5cHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEDteXNKSzVyPUe0MlUxPSEQvF2=NIG4SYlUSU6JRWK=
RPMI-8866NGn5e2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1;HPGlEPTB;N{SuO|UxQSEQvF2=MXPTRW5ITVJ?
HCC1599Ml3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NY\YcZZpUUN3ME23OE45PzN{IN88US=>NX21XIxsW0GQR1XS
NCI-H1155M2C3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGXIcXFKSzVyPUe0Mlk{PjdizszNMkDQV2FPT0WU
DOHH-2NHnPbXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmTwTWM2OD15ND65OVE1KM7:TR?=NUXhW|htW0GQR1XS
SK-NEP-1NEfJfGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mnu1TWM2OD15NT6wO|U1KM7:TR?=NFLMN2pUSU6JRWK=
HCC1187M3y5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVHJR|UxRTd5Lk[xNlIh|ryPMknaV2FPT0WU
NCI-H322MMUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGnxNZZKSzVyPUe4MlM4ODlizszNMlrWV2FPT0WU
NCI-H526MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUXJR|UxRTd6LkW4O|ch|ryPMn\pV2FPT0WU
NCI-H2171NFf5UVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHvXb|BKSzVyPUe5MlQyOzZizszNM3i4enNCVkeHUh?=
COLO-668M4\Zemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmDmTWM2OD16MT61PFg1KM7:TR?=M2XpR3NCVkeHUh?=
RS4-11NFLueo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVnJR|UxRTh{LkK1NFUh|ryPNYnONYdpW0GQR1XS
NCI-H716NHTzW3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV;OdWV5UUN3ME24Nk46ODd3IN88US=>NVXnXGN1W0GQR1XS
LU-134-AM4nrd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXXOOm1WUUN3ME24N{4yOzVzIN88US=>MnLMV2FPT0WU
RPMI-8226M{HvU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF\zTVVKSzVyPUi0MlIyODdizszNNFnOOYtUSU6JRWK=
KY821NXztcY1kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHrjZmFKSzVyPUmxMlY2PTFizszNNWDOd4RkW0GQR1XS
ECC4M{TSPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlKxTWM2OD17Mz64NlY6KM7:TR?=MWDTRW5ITVJ?
EW-3M4nEfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEn3cpBKSzVyPUm0MlkxQDFizszNNVO2SoFtW0GQR1XS
NB7MlW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRTl3Lke3PFYh|ryPMUjTRW5ITVJ?
NCI-H720NH\sZWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFrFbYpKSzVyPUm4MlQxPjFizszNMWXTRW5ITVJ?
NCI-H446MmrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV\GSIRJUUN3ME25PU44PTh6IN88US=>MoTmV2FPT0WU
NCI-H889NGD3fXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYjlbJFxUUN3ME2xNFQvOjR{IN88US=>MYjTRW5ITVJ?
EW-22NIjUe2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3L0bGlEPTB;MUC2MlE6KM7:TR?=M4jxWHNCVkeHUh?=
BV-173MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NY\qUG9JUUN3ME2xNFgvPzJ6IN88US=>MXXTRW5ITVJ?
WSU-NHLM{PJOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV\sW2w5UUN3ME2xNFkvPjdzIN88US=>MV3TRW5ITVJ?
MN-60MnzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NELwR|RKSzVyPUGwPU43QSEQvF2=NX3pXotsW0GQR1XS
DG-75MkSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGDqVmRKSzVyPUGxN{4{PTJizszNMUjTRW5ITVJ?
DMS-79MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYP1dYU3UUN3ME2xNVcvOzh{IN88US=>M{\3c3NCVkeHUh?=
SK-MEL-1NYXTRm04T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHLvR3pKSzVyPUGxPE4xODlizszNMn\lV2FPT0WU
DMS-153NUD5O3hIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3vGVGlEPTB;MUKxMlc1PSEQvF2=NXvFUVhkW0GQR1XS
NCI-H510AMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NETJTHRKSzVyPUGyO{4{OiEQvF2=MVLTRW5ITVJ?
BE-13MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MljPTWM2OD1zM{SuNFQ1KM7:TR?=MVLTRW5ITVJ?
KP-N-YSMojmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4fzOWlEPTB;MUO5Mlc{PiEQvF2=NH\tUJFUSU6JRWK=
SUP-T1M3f2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M37POWlEPTB;MUSzMlcxQCEQvF2=NVvQWpRbW0GQR1XS
EW-12MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWTJR|UxRTF2ND62PVkh|ryPMmXlV2FPT0WU
NB14M3HIXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUHJR|UxRTF2Nz6wPFIh|ryPNUfRdHp6W0GQR1XS
MDA-MB-134-VIM3fjT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2\1cmlEPTB;MUS4MlI3QCEQvF2=M3LwOXNCVkeHUh?=
NCI-H1770M4W1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3fCOmlEPTB;MUW2MlI4QSEQvF2=NWrhOGpiW0GQR1XS
TURMmTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUfJR|UxRTF4Nz64O{DPxE1?M4rWNXNCVkeHUh?=
NCI-H1417MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlfnTWM2OD1zOECuN|MyKM7:TR?=Mlf3V2FPT0WU
IMR-5MkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{nDb2lEPTB;MUixMlU4OSEQvF2=MXzTRW5ITVJ?
NCI-H226MoXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnXkTWM2OD1zOEiuPFY3KM7:TR?=M3LOUHNCVkeHUh?=
NCI-H187NHLEbYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3LwdWlEPTB;MUmwMlA3PCEQvF2=NFm2fmFUSU6JRWK=
SF539NYDlUG5JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MojITWM2OD1zOUKuO|I5KM7:TR?=MkTKV2FPT0WU
TALL-1MnLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1PJTWlEPTB;MUm4MlMxPCEQvF2=NFzYdnlUSU6JRWK=
TE-441-TMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlG4TWM2OD1zOUmuO|M6KM7:TR?=NWTMW|FOW0GQR1XS
REHNX7WOZJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3n3NGlEPTB;MkO2MlYzPiEQvF2=M4nxdXNCVkeHUh?=
MS-1MmGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX3uc2tmUUN3ME2yN|kvOTJzIN88US=>MWPTRW5ITVJ?
THP-1MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3TUc2lEPTB;Mk[0Mlc{QCEQvF2=NULscIlzW0GQR1XS
NCI-H1838MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF7NepJKSzVyPUK3NU41PTZizszNNY[5[4tMW0GQR1XS
P30-OHKNWrpWmt2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NY\ZS2t2UUN3ME2yPFMvQDR5IN88US=>M2DFVXNCVkeHUh?=
C8166M17IO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYfqO3BLUUN3ME2zOFUvOzN6IN88US=>MmT6V2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Administration of MG-132 effectively rescues the expression levels and plasma membrane localization of dystrophin, β-dystroglycan, α-bdystroglycan, and α-sarcoglycan in skeletal muscle fibers from mdx mice, reduces muscle membrane damage, and ameliorates the histopathological signs of muscular dystrophy. [7] MG-132 treatment significantly reduces immobilization-induced skeletal muscle atrophy in mice, by downregulating the muscle-specific ubiquitin ligases atrogin-1/MAFbx and MuRF-1 mRNA. [8]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

Measurement of inhibitory activities of MG-132 against 20S proteasome The reaction mixture for the 20S proteasome inhibitory assay contains 0.1 M Tris-acetate, pH 7.0, 20S proteasome, MG-132, and 25 μM substrate dissolved in dimethyl sulfoxide in a final volume of 1 mL. After incuba tion at 37 °C for 15 minutes, the reaction is stopped by the addition of 0.1 mL of 10% SDS and 0.9 mL of 0.1M Tris acetate, pH 9.0. The fluorescence of the reaction products is measured. To determine the IC50 against 20S proteasome, various concentrations of MG-132 are included in the assay mixture.

Cell Assay:

[3]

Cell lines KIM-2, HC11, and ES
Concentrations Dissolved in DMSO, final concentrations ~25 μM
Incubation Time 24, and 48 hours
Method

Cells are exposed to various concentrations of MG-132 for 24, and 48 hours. Supernatant and monolayer cells are harvested by centrifugation and fixed in 70% ethanol in PBS for staining with acridine orange. Equal volumes of cells and acridine orange (5 mg/mL in PBS) are mixed on a microscope slide and examined by fluorescence microscopy. For annexin V analysis, cells are harvested by centrifugation and stained with annexin V and propidium iodide. For cell cycle analysis, cells are rehydrated in PBS at room temperature for 10 minutes, followed by staining with propidium iodide (5 mg/mL). All samples are analyzed using a Coulter Epics XL flow cytometer.

Animal Study:

[7]

Animal Models Male mdx (C57BL/10ScSn DMD mdx) mice
Formulation Dissolved in DMSO, and diluted in PBS
Dosages ~10 μg/kg/day
Administration Injection

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Tsubuki S, et al. J Biochem, 1996, 119(3), 572-576.

[2] Fiedler MA, et al. Am J Respir Cell Mol Biol, 1998, 19(2), 259-268.

view more

Chemical Information

Download MG-132 SDF
Molecular Weight (MW) 475.62
Formula

C26H41N3O5

CAS No. 133407-82-6
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 95 mg/mL (199.73 mM)
Ethanol 95 mg/mL (199.73 mM)
Water <1 mg/mL (<1 mM)
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80, pH 4 6 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name benzyl (S)-4-methyl-1-((S)-4-methyl-1-((S)-4-methyl-1-oxopentan-2-ylamino)-1-oxopentan-2-ylamino)-1-oxopentan-2-ylcarbamate

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Proteasome Products

  • VR23

    VR23 is a potent proteasome inhibitor with IC50 of 1 nM, 50-100 nM, and 3 μM for trypsin-like proteasomes, chymotrypsin-like proteasomes, and caspase-like proteasomes, respectively.

  • Calpeptin

    Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively.

  • Marimastat(BB-2516)

    Marimastat (BB-2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.

  • Bortezomib (PS-341)

    Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM in a cell-free assay.

  • Carfilzomib (PR-171)

    Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.

  • Ixazomib (MLN2238)

    MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Phase 3.

    Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.

  • ONX-0914 (PR-957)

    ONX-0914 (PR-957) is a potent and selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome in a cell-free assay.

    Features:The first highly selective, small molecule inhibitor of the immunoproteasome. Potential use in cancer and autoimmune diseases (e.g. rheumatoid arthritis, inflammatory bowel disease, and lupus).

  • MLN9708

    MLN9708 immediately hydrolyzed to MLN2238, the biologically active form, on exposure to aqueous solutions or plasma. MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Phase 3.

    Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.

  • Celastrol

    Celastrol is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM.

    Features:A potent antioxidant and anti-inflammatory drug.

  • Oprozomib (ONX 0912)

    Oprozomib (ONX 0912) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. Phase 1/2.

Recently Viewed Items

Tags: buy MG-132 | MG-132 supplier | purchase MG-132 | MG-132 cost | MG-132 manufacturer | order MG-132 | MG-132 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us